Category: Parkinson's Disease: Neurophysiology
Objective: To describe Parkinson’s kinetograph utilised clinical parameters and correlations in a denovo Parkison’s disease (PD) cohort from Moscow Russia.
Background: The Parkinson’s KinetiGraph™ (PKG) is a wrist-worn wearable sensor device using an accelerometer for continuous ambulatory monitoring of movement to produce bradykinesia (BKS), dyskinesia (DKS), percent time immobile (PTI) scores every two minutes plotted over six days to create a graphical representation .The device has MHRA and FDA-CEA marking and reflects motor and aspects of nonmotor symptoms (NMS) in PD. There is sparse data however, in denovo PD and none from Russia.
Method: Cross-sectional data from an ongoing denovo and advanced PD endophenotyping study (Mons-PD). Assessments included PKG data with Unified Parkinson’s Disease Rating Scale (UPDRS), NMS scale (NMSS), PD sleep scale (PDSS), and a fatigue visual analog scale.
Results: Complete PKG data was available in 129 out of 132 denovo PD (mean age 70.1±8.4yrs, disease duration 1.8±1.5yrs, PDSS 124.8±18.7, NMSS 59.4±50, UPDRS III 18.11±14.7, Fatigue 4.4±4). Mean BKS (25% range) was 22.55±5.9 (control 12.7), 50% range 29.59±6.4 (control 18.6) and 75% range 38.7±7.5 (control 26.1). A significant (p<0.05) correlation (Spearman rank) was evident between UPDRS III (questions 23,24,25 and 31 (overall bradykinesia/hypokinesia). PTI score was 10.7±8.4 while a fluctuation dyskinesias score (FDS) was 7.9±3. PTI correlated with item 15 PDSS (unexpectedly fallen asleep) and NMSS question 3 (dozing off) as well as UPDRS III question 31 (p<0.01).
Conclusion: These pilot wearable sensor generated data from a consecutive denovo PD cohort show bradykinesia-dominant presentation ranging from moderate to severe. Correlation with bradykinesia items of UPDRS supports the validity of PKG as a marker, while PTI, as described previously in treated PD, appears to be a marker for poor sleep/sudden onset of sleep underpinned by bradykinesia . The significance of FDS in denovo PD is unclear and has not been reported previously.
References: 1. Odin P, Chaudhuri KR, Volkmann J, Antonini A, Storch A, Dietrichs E et al. Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease, Npj Park. Dis 2018;4:14. doi:10.1038/s41531-018-0051-7. 2. Kotschet K, Johnson W, McGregor S, Kettlewell J, Kyoong A, O’Driscoll DM et al. Daytime sleep in Parkinson’s disease measured by episodes of immobility, Park. Relat. Disord 2014:20:578–583.
To cite this abstract in AMA style:N. Titova, D. Trivedi, Y. Bezdolny, E. Katunina, K. Ray Chaudhuri. Wearable sensor monitoring in denovo Parkinson’s disease using the Parkinson’s KinetiGraph: pilot data and correlations from the MoNS-PD cohort [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/wearable-sensor-monitoring-in-denovo-parkinsons-disease-using-the-parkinsons-kinetigraph-pilot-data-and-correlations-from-the-mons-pd-cohort/. Accessed December 5, 2023.
« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/wearable-sensor-monitoring-in-denovo-parkinsons-disease-using-the-parkinsons-kinetigraph-pilot-data-and-correlations-from-the-mons-pd-cohort/